TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06333184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Fruit ingested in whole form or as either commercially available, or home-made smoothies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food
Description: Fruit ingested in whole form or as either commercially available, or home-made smoothies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Fruit ingested in whole form or as either commercially available, or home-made smoothies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Fruit ingested in whole form or as either commercially available, or home-made smoothies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Fruit ingested in whole form or as either commercially available, or home-made smoothies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Fruit ingested in whole form or as either commercially available, or home-made smoothies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Fruit ingested in whole form or as either commercially available, or home-made smoothies
Study: NCT04648280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir
Description: fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
Study: NCT04841122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Camera observation
Description: Supplemental camera observation directly linked to the nurse's phone
Study: NCT05366335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Live Combined Bifidobacterium and Lactobacillus
Description: The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basic treatment
Description: The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
Study: NCT05951114

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximum inspiratory/Expiratory manoeuvre for patients can follow the order
Description: Bedside ultrasound will be performed for each patient at the time before, after surgery, before and after extubation, and at the time of ICU discharge, under the end-expiratory occlusion, maximum inspiratory, and/or expiratory manoeuvre

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximum inspiratory/Expiratory manoeuvre for patients can follow the order
Description: Bedside ultrasound will be performed for each patient at the time before, after surgery, before and after extubation, and at the time of ICU discharge, under the end-expiratory occlusion, maximum inspiratory, and/or expiratory manoeuvre
Study: NCT05525897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational
Description: The focus of the course is to teach students the fundamental theories, and practices of soft skills, as well as providing cases and material that give students the opportunity to learn from real life experiences.
Study: NCT06070779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuro linguistic programming
Description: neuro linguistic programming

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuro linguistic programming
Description: neuro linguistic programming
Study: NCT06052475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)
Description: The approach for physiological pacing upgrade will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continued RV Pacing (Right Ventricular Pacing)
Description: Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
Study: NCT06605495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral herbal medicine
Description: Patients were identified into the appropriate group according to the individual evidence profile, and the herbal formula under the corresponding evidence profile was taken orally as one dose of 150 ml of water twice a day for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modern Western Medicine
Description: Referring to the Chinese Expert Consensus on Dry Eye: Treatment (2020), this course of treatment totaled 6 weeks.
Study: NCT06598605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Reflective Functioning Workshop
Description: Four online workshop sessions via Zoom will be based on psycho-educational knowledge concerning emotional regulation and specialized in autism. The group size will be up to 15 participants, with each session lasting an hour and a half, after which participants will be asked to complete a reflective journal.
Study: NCT06610916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reinforced Communautary Support Program (PARC)
Description: Participants will complete the initial self-questionnaire collecting baseline socio-demographic, clinical characteristics, and all intermediate effectiveness outcome criteria \&amp;#34;before\&amp;#34;. Concurrently with their participation in the program, they will complete various intermediate effectiveness evaluation questionnaires (\&amp;#34;after\&amp;#34;) at 3 months (end of PARC) and 6 months (Post-PARC). Healthcare professionals running the PARC program will also complete questionnaires related to implementation indicators throughout the patients\&amp;#39; course (Adoption, Implementation, Maintenance).~Qualitative interviews will be conducted with patients and relevant healthcare professionals to explore barriers and drivers to the optimal deployment of the PARC program and to examine each of the Reach, Adoption, Implementation, Maintenance indicators through an organizational approach
Study: NCT06609915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: supraglottic superimposed high frequency jet ventilation ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany)
Description: supraglottic superimposed high frequency jet ventilation ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany). Initially FiO2 at 1.0, reduced to 0.3 during laser interventions. Frequency and pressure set according to the local standards

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal supplemental oxygen via nasal cannula with the Optiflow (Fisher & Paykel, Auckland, New Zealand)
Description: up to 70 L/min FiO2 1.0 high flow oxygen via nasal cannula with the Optiflow (Fisher \& Paykel, Auckland, New Zealand) initially. Reduced FiO2 to 0.3 during laser intervention.
Study: NCT04758572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Mobilization, massage and stretching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage muscle chain
Description: Massage very soft following the directions of the muscle chains, massage and stretching
Study: NCT05344950

Intervention type: BEHAVIORAL
Intervention: Audio + Radio (AURA)
Description: Participants will receive personalized self-care information based on their symptoms and signs of complications (e.g., fatigue) from interacting with our voice assistant device, connected to a system that integrating the patient-reported outcome and objective data from passive RF sensing to provide continuous monitoring of patients' symptoms and complications after they are discharged home.
Study: NCT04875325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized surveillance
Description: Standardized 3-monthly surveillance with routine imaging and serum tumor marker testing.
Study: NCT05892432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 3 MG [Rybelsus]
Description: Semaglutide 3 mg will be taken for the first 4 weeks of the 8-week trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 7 MG [Rybelsus]
Description: Semaglutide 7 mg will be taken for the second 4 weeks of the 8-week trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A medically inert placebo medication will be taken for 8 weeks.
Study: NCT05973942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wingman-Connect
Description: Training occurs in three 2-hr blocks over several days. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work.
Study: NCT05896163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maplirpacept (PF-07901801)
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maplirpacept (PF-07901801)
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maplirpacept (PF-07901801)
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous infusion
Study: NCT06018350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician-led adherence intervention
Description: The clinician will review real time pharmacy refill data during clinic and use effective communication techniques to discuss adherence with the patient
Study: NCT05757843

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Signatera ctDNA test
Description: The first mandatory ctDNA test will be done at screening for the bespoke ctDNA profiling. The next mandatory ctDNA test will be completed prior to the 5th cycle of consolidation Durvalumab. ctDNA testing will be repeated approximately every 4 weeks until two consecutive negative analyses occur. ctDNA testing will be otherwise discontinued after progressive disease or after up to 1 year of consolidation treatment per standard medical practice is considered complete, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All subjects will receive consolidation Durvalumab approximately every 4 weeks. Durvalumab will be stopped after two consecutive negative ctDNA analyses occur.
Study: NCT05719311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrulipase
Description: Enteric microgranule formulation of adrulipase.
Study: NCT06258369

Intervention type: OTHER
Group type: OTHER
Intervention: Patients with primary coxarthrosis (any stage).
Description: Patients who do not undergo surgery will be called specifically for the study to attend a consultation dedicated to gait assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with primary coxarthrosis (any stage) and operated with Total Hip Prosthesis (THP).
Description: Patients scheduled for THP (Total Hip Prosthesis) will be seen at the consultation the day before surgery, in the same hospital as the THP, or at an existing dedicated consultation scheduled for all THP patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with primary coxarthrosis (any stage) and operated with RTH (Hip resurfacing).
Description: Patients scheduled for RTH (Hip Resurfacing) will be seen at the consultation the day before surgery, in the same hospital as the RTH, or at an existing dedicated consultation scheduled for all RTH patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
Study: NCT05526716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Single 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Single 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matching Placebo for V116
Description: Single 0.5 mL of sterile saline IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matching Placebo for V116
Description: Single 0.5 mL of sterile saline IM injection
Study: NCT05021354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: dry needling, stretching and eccentric exercise

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topical gel
Description: aplication of topical gel to the epicondyle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs
Description: oral intake of NSAIDs
Study: NCT05380973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short fiber resin composite
Description: resin composite reinforced with short glass fibers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short fiber resin composite
Description: resin composite reinforced with short glass fibers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene ribbon fiber
Description: resin composite reinforced with polyethylene ribbon fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene ribbon fiber
Description: resin composite reinforced with polyethylene ribbon fiber
Study: NCT05136976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab infusion
Description: 2 infusions of 1 gram of rituximab at a 2 week interval (day 1 followed by day 15).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: 2 infusions of placebo at a 2 week interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Premedications
Description: Premedications prior to rituximab or placebo infusions:~* IV Dexchlorpheniramine Maleate IV: 10 mg~* IV Methylprednisolone: 40 mg~* PO Paracetamol : 1 gram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premedications
Description: Premedications prior to rituximab or placebo infusions:~* IV Dexchlorpheniramine Maleate IV: 10 mg~* IV Methylprednisolone: 40 mg~* PO Paracetamol : 1 gram
Study: NCT04921670

Intervention type: DIAGNOSTIC_TEST
Intervention: Infliximab Assay
Description: Participants will be assigned to standard of care or proactive drug monitoring, which is measuring infliximab levels/antibodies before every infusion
Study: NCT05282095

Intervention type: OTHER
Intervention: Follow up
Description: Participants will be followed up at baseline, 3th, 6th, 9th and 12th months with HPV viral integration tests, HPV genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopies and biopsies will be performed on the participants at 6 - and 12-month follow-up.
Study: NCT05624580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0582-0001
Description: Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0582-0001
Description: Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0582-0001
Description: Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0582-0001
Description: Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0582-0001
Description: Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0582-0001
Description: Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.
Study: NCT06311838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/Community Reinforcement Approach (MI/CRA)
Description: MI/CRA includes two Motivational Interviewing sessions and twelve 1-hour Community Reinforcement Approach sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/Community Reinforcement Approach (MI/CRA)
Description: MI/CRA includes two Motivational Interviewing sessions and twelve 1-hour Community Reinforcement Approach sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-Based Outreach and Advocacy (SBOA )
Description: The number of Strengths-Based Outreach and Advocacy sessions participants will receive are flexibly determined based upon youth needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-Based Outreach and Advocacy (SBOA )
Description: The number of Strengths-Based Outreach and Advocacy sessions participants will receive are flexibly determined based upon youth needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as Usual (SAU)
Description: Participants assigned to this group will receive the standard services provided to all youth involved with the drop-in center.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as Usual (SAU)
Description: Participants assigned to this group will receive the standard services provided to all youth involved with the drop-in center.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual (SAU)
Description: Participants assigned to this group will receive the standard services provided to all youth involved with the drop-in center.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as Usual (SAU)
Description: Participants assigned to this group will receive the standard services provided to all youth involved with the drop-in center.
Study: NCT05146388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR-Based Approach
Description: The intervention will be built directly into the EHR. E-prescriptions will be generated with pharmacy instructions for all prescription medications. The intervention will impart: 1) inclusion with e-Rx request for pharmacy to keep metric-only (mL-only) dosing on Rx label and 2) inclusion of guidance on the e-Rx requesting that the pharmacy give an optimal tool based on an algorithm. Algorithm for dosing tool recommendation: 1) for a prescribed dose of \<= 1mL, optimal tool is 1 mL syringe, 2) for \>1 mL to 5 mL, use a 5 mL syringe, 3) for \>5mL to 10mL, use 10 mL syringe.
Study: NCT06548776

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy (MRS) Scan
Description: Participants will receive MRS Scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy (MRS) Scan
Description: Participants will receive MRS Scan